<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039025</url>
  </required_header>
  <id_info>
    <org_study_id>DM01-331</org_study_id>
    <nct_id>NCT01039025</nct_id>
  </id_info>
  <brief_title>TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma</brief_title>
  <official_title>Phase II Study of High-Dose Topotecan, Cyclophosphamide and Melphalan for the Treatment of Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SmithKline Beecham</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients&#xD;
      with Multiple Myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in this study will have a catheter (a tube) placed in the vein below the collarbone.&#xD;
      Most of the drugs used in the study will be given through the catheter. Blood stem cells will&#xD;
      be collected through this tube also.&#xD;
&#xD;
      Before treatment starts, patients will have a complete physical exam, including blood and&#xD;
      urine tests. A dentist will perform a dental exam either at M.D. Anderson or elsewhere. A&#xD;
      chest x-ray and bone x-rays will be done. An EKG and a heart scan will be done to test heart&#xD;
      function. A breathing test will be done. Patients will also be screened for HIV and&#xD;
      Hepatitis.&#xD;
&#xD;
      Blood stem cells will be collected from patients when white blood cell counts are normal.&#xD;
      This will be after earlier chemotherapy or after a bone marrow growth factor (G-CSF) has been&#xD;
      given. Collecting stem cells takes about 3 hours. It takes from 1 to 6 sessions to get the&#xD;
      needed amount of cells. The process is called apheresis. A machine is attached to the&#xD;
      catheter, and blood is drawn. The machine removes the stem cells from the blood and the blood&#xD;
      is then returned to the body through the catheter. G-CSF is injected under the skin twice a&#xD;
      day during the time the stem cells are collected. The stem cells are stored frozen and will&#xD;
      be used later to help patients recover from the high-dose chemotherapy.&#xD;
&#xD;
      After stem cells are collected, patients will receive high-dose chemotherapy.&#xD;
      Cyclophosphamide is given over 2 hours on Days 1 - 3. Melphalan is given on Days 4 and 5.&#xD;
      Topotecan is given over 30 minutes on Days 1 - 5, right after cyclophosphamide or melphalan.&#xD;
      On Day 6, no drugs are given. On Day 7, some or all of the stem cells will be reinfused.&#xD;
      G-CSF will be given once a day until blood counts return to normal.&#xD;
&#xD;
      Patients must stay in the hospital for the high-dose drug treatment. The length of stay will&#xD;
      be about 3 weeks. Blood tests will be done daily while in hospital, then once a week for the&#xD;
      first month. A bone marrow sample will be taken on Day 30. Blood samples will be taken 4&#xD;
      times in the first year and once a year after that. Thyroid gland tests and a bone marrow&#xD;
      test will be done once a year.&#xD;
&#xD;
      This is an investigational study. Cyclophosphamide, melphalan, and topotecan are approved by&#xD;
      the FDA. Their use together in this study is experimental. All participants will be enrolled&#xD;
      at UTMDACC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2002</start_date>
  <completion_date type="Actual">May 19, 2006</completion_date>
  <primary_completion_date type="Actual">May 19, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Within 180 days after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>TMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topotecan, Melphalan, and Cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>After stem cells are collected, Topotecan 3.5 mg/m^2 intravenously given over 30 minutes on Days 1 - 5.</description>
    <arm_group_label>TMC</arm_group_label>
    <other_name>Hycamtin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>After stem cells are collected, Cyclophosphamide 1 g/m^2/day intravenously given over 2 hours on Days 1 - 3.</description>
    <arm_group_label>TMC</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>After stem cells are collected, Melphalan 70 mg/m^2/day intravenously given on Days 4 and 5.</description>
    <arm_group_label>TMC</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral Blood Stem Cells</intervention_name>
    <description>On Day 7, some or all of the stem cells will be reinfused.</description>
    <arm_group_label>TMC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with intermediate or high tumor mass multiple myeloma with responsive or&#xD;
             primary refractory disease; and patients with responsive or refractory relapse.&#xD;
&#xD;
          2. Physiological age &lt;/= 70.&#xD;
&#xD;
          3. Zubrod performance status &lt; 3.&#xD;
&#xD;
          4. Life expectancy greater than 12 weeks.&#xD;
&#xD;
          5. Left ventricular ejection fraction &gt;/= 50%.&#xD;
&#xD;
          6. No uncontrolled arrythmias or symptomatic cardiac disease.&#xD;
&#xD;
          7. FEV1, FVC and DLCO &gt;/= 50%.&#xD;
&#xD;
          8. No symptomatic pulmonary disease.&#xD;
&#xD;
          9. Serum creatinine &lt; 1.5 mg/dL.&#xD;
&#xD;
         10. Serum bilirubin &lt; 2x upper limit of normal.&#xD;
&#xD;
         11. No evidence of chronic or active hepatitis or cirrhosis.&#xD;
&#xD;
         12. Patient is not pregnant.&#xD;
&#xD;
         13. Patients or guardian able to sign informed consent.&#xD;
&#xD;
         14. No active CNS disease.&#xD;
&#xD;
         15. Platelet count &gt; 100K.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) N/A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Donato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T. M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.org</url>
    <description>M.D. Anderson Cancer Center clinical trials web site</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Topotecan</keyword>
  <keyword>Hycamtin</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Alkeran</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Stem Cell Harvest</keyword>
  <keyword>Peripheral Blood Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

